Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.846
-0.054 (-6.02%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2024. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$61,030
Profits / Employee
-$1,629,842
Market Cap
5.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| Processa Pharmaceuticals | 10 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Mustang Bio | 6 |
| Can-Fite BioPharma | 5 |
| Creative Medical Technology Holdings | 4 |
APRE News
- 19 days ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 19 days ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 20 days ago - Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 25 days ago - Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - GlobeNewsWire
- 4 weeks ago - Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - GlobeNewsWire